PIK3CA and breast carcinoma: The combination of Alpelisib (an orally PI3K inhibitor) and fulvestrant significantly improves progression-free survival (PFS) in patients with metastatic HR+ breast cancer, with adverse events that are manageable and well-tolerated (André et al., 2021).